Emergex logo.png
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
July 28, 2022 02:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine Emergex will manufacture the candidate universal influenza vaccine to cGMP standards for use in Phase I...
Emergex logo.png
Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil
July 01, 2022 02:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil Abingdon, Oxon, UK, 1 July 2022 – Emergex Vaccines Holding Limited...
Emergex logo.png
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
May 17, 2022 07:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch Emergex’s COVID-19 and Dengue CD8+ T cell...
Emergex logo.png
Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
April 18, 2022 02:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines Both studies fully recruited, with data from the Dengue Fever...
Emergex logo.png
Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives
April 14, 2022 02:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives Emergex’s CD8+ T cell Adaptive Vaccine...
Emergex logo.png
Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate
April 07, 2022 02:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate Abingdon, Oxon, UK, 7 April 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or...
Emergex logo.png
Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus
February 22, 2022 02:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus Abingdon, Oxon, UK, 22 February...
Emergex logo.png
Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations
November 30, 2021 08:51 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations Emergex confirms that...
Emergex logo.png
Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
November 15, 2021 07:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate Synthetic vaccine designed to prime T-Cells to rapidly remove...
Emergex logo.png
Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
November 15, 2021 02:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate Synthetic vaccine designed to prime T-Cells to rapidly remove...